News

CEO Letter To Shareholders January 6, 2015

Dear Shareholders, 2014 was a year of transition for Immune Pharmaceuticals. We obtained a NASDAQ listing, raised over $20 million in equity, reduced past liabilities and strengthened our cash position.  We believe that we now have the capital…

Research companies from USA and Isarel put down roots in Sweden

Download PDF In the middle of the acquisition process the CEOs of EpiCept Corporation and Immune Pharmaceuticals Ltd. are meeting in Sweden to discuss EpiCept’s listing on the stock exchange in Stockholm after the merger. But the Israeli…

BioWorld Today: Immune Takes Road Less Traveled with Epicept Buy

By Marie Powers Staff Writer Privately held Immune Pharmaceuticals Ltd. swam against the tide of biotechs rushing to initial public offerings (IPO) by completing its merger with Epicept Corp., gaining access to the public markets and an expanded…

Next, Israel as the Boitech Nation

http://blogs.timesofisrael.com/next-israel-as-the-biotech-nation/ while Israel is now world-renowned for its ability to start, grow and sell hi-tech, Internet and medical technology companies, biotech success is lagging despite Israel being # 2…